

AXIRON[®] MARKETING AUTHORISATION GRANTED IN AUSTRALIA

Acrux (ASX: ACR) today reported that Eli Lilly has received approval to market Axiron[®] in Australia. The Therapeutic Goods Administration has granted Lilly a marketing authorisation for Axiron as an androgen replacement therapy for confirmed testosterone deficiency in males. In addition, the Pharmaceutical Benefits Advisory Committee (PBAC) has approved the listing of Axiron on the Pharmaceutical Benefits Scheme.

Axiron was launched by Lilly in the United States in 2011 and was recently approved for marketing in Canada as replacement therapy in men for conditions associated with a deficiency or absence of testosterone. Regulatory decisions on marketing applications under review in select European countries are anticipated during 2012. Acrux anticipates future expansion into Asian and South American markets.

Acrux Chairman Ross Dobinson highlighted the milestone of the first product developed by Acrux to be made available to Australians. “The technology behind Axiron originated at Monash University and its development by Acrux over a decade has been supported by our shareholders as well as Federal and State governments through competitive grants and tax concessions. This support has been critical and the benefits for all Australian stakeholders are now being realised as Axiron is commercialised around the world.”

Acrux expects to begin earning royalties on net sales of Axiron in Australia during the 2012/13 financial year.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.

- Acrux has two products marketed by licensees in the USA, two products approved in Europe, one product in registration in the USA and further products at earlier stages of development.